Cargando…

Association of tumor necrosis factor alpha gene polymorphism G-308A with pseudoexfoliative glaucoma in the Pakistani population

PURPOSE: The purpose of the present study was to determine the role of the tumor necrosis factor alpha (TNF-α) gene polymorphism G-308A and total serum immunoglobulin E (TsIgE) levels in the onset of pseudoexfoliation glaucoma (PEXG) in Pakistani patients. METHODS: The TNF-α polymorphism G-308A was...

Descripción completa

Detalles Bibliográficos
Autores principales: Khan, Muhammad Imran, Micheal, Shazia, Rana, Noreen, Akhtar, Farah, den Hollander, Anneke I., Ahmed, Asifa, Qamar, Raheel
Formato: Texto
Lenguaje:English
Publicado: Molecular Vision 2009
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2796874/
https://www.ncbi.nlm.nih.gov/pubmed/20029655
Descripción
Sumario:PURPOSE: The purpose of the present study was to determine the role of the tumor necrosis factor alpha (TNF-α) gene polymorphism G-308A and total serum immunoglobulin E (TsIgE) levels in the onset of pseudoexfoliation glaucoma (PEXG) in Pakistani patients. METHODS: The TNF-α polymorphism G-308A was analyzed in 122 patients with PEXG and 126 healthy unrelated controls by using polymerase chain reaction (PCR) and restriction fragment length polymorphism (RFLP). TsIgE levels were determined by solid-phase enzyme-linked immunosorbent assay (ELISA). RESULTS: The AA and GA genotypes were strongly associated with PEXG (p<0.001), with an odds ratio (OR) of 0.07 (95% confidence interval [CI]=0.02-0.27) and 0.24 (95% CI=0.12-0.51), respectively, while the GG genotype was found at a higher frequency in controls as compared to patients (p<0.001) OR=8.95 (95% CI=4.55–17.81). No significant difference was found in TsIgE levels of both patients and controls (p=0.86). CONCLUSION: The present study concludes that the TNF-α polymorphism G-308A is strongly associated with PEXG. To our knowledge this is the first study in southeast Asia which demonstrates a strong association of a TNF-α polymorphism with PEXG.